JP7164200B2 - サッカライド－ポリペプチドコンジュゲートの組成物およびその使用の方法 - Google Patents

サッカライド－ポリペプチドコンジュゲートの組成物およびその使用の方法 Download PDF

Info

Publication number
JP7164200B2
JP7164200B2 JP2019502538A JP2019502538A JP7164200B2 JP 7164200 B2 JP7164200 B2 JP 7164200B2 JP 2019502538 A JP2019502538 A JP 2019502538A JP 2019502538 A JP2019502538 A JP 2019502538A JP 7164200 B2 JP7164200 B2 JP 7164200B2
Authority
JP
Japan
Prior art keywords
serotypes
polypeptide
pharmaceutical composition
saccharide
serotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019502538A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513821A5 (enExample
JP2019513821A (ja
Inventor
ブルース ディー． フォレスト，
ジャック ディー． ラブ，
Original Assignee
ポゴナ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59965349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7164200(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ポゴナ， エルエルシー filed Critical ポゴナ， エルエルシー
Publication of JP2019513821A publication Critical patent/JP2019513821A/ja
Publication of JP2019513821A5 publication Critical patent/JP2019513821A5/ja
Priority to JP2022111088A priority Critical patent/JP2022130741A/ja
Application granted granted Critical
Publication of JP7164200B2 publication Critical patent/JP7164200B2/ja
Priority to JP2023152185A priority patent/JP2023166591A/ja
Priority to JP2025095460A priority patent/JP2025124888A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019502538A 2016-03-31 2017-03-31 サッカライド－ポリペプチドコンジュゲートの組成物およびその使用の方法 Active JP7164200B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022111088A JP2022130741A (ja) 2016-03-31 2022-07-11 サッカライド－ポリペプチドコンジュゲートの組成物およびその使用の方法
JP2023152185A JP2023166591A (ja) 2016-03-31 2023-09-20 サッカライド－ポリペプチドコンジュゲートの組成物およびその使用の方法
JP2025095460A JP2025124888A (ja) 2016-03-31 2025-06-09 サッカライド－ポリペプチドコンジュゲートの組成物およびその使用の方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662316555P 2016-03-31 2016-03-31
US62/316,555 2016-03-31
US201662330245P 2016-05-02 2016-05-02
US62/330,245 2016-05-02
US201662372263P 2016-08-08 2016-08-08
US62/372,263 2016-08-08
US201662373807P 2016-08-11 2016-08-11
US62/373,807 2016-08-11
PCT/US2017/025621 WO2017173415A2 (en) 2016-03-31 2017-03-31 Saccharide-polypeptide conjugate compositions and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022111088A Division JP2022130741A (ja) 2016-03-31 2022-07-11 サッカライド－ポリペプチドコンジュゲートの組成物およびその使用の方法

Publications (3)

Publication Number Publication Date
JP2019513821A JP2019513821A (ja) 2019-05-30
JP2019513821A5 JP2019513821A5 (enExample) 2020-05-14
JP7164200B2 true JP7164200B2 (ja) 2022-11-01

Family

ID=59965349

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019502538A Active JP7164200B2 (ja) 2016-03-31 2017-03-31 サッカライド－ポリペプチドコンジュゲートの組成物およびその使用の方法
JP2022111088A Revoked JP2022130741A (ja) 2016-03-31 2022-07-11 サッカライド－ポリペプチドコンジュゲートの組成物およびその使用の方法
JP2023152185A Pending JP2023166591A (ja) 2016-03-31 2023-09-20 サッカライド－ポリペプチドコンジュゲートの組成物およびその使用の方法
JP2025095460A Pending JP2025124888A (ja) 2016-03-31 2025-06-09 サッカライド－ポリペプチドコンジュゲートの組成物およびその使用の方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022111088A Revoked JP2022130741A (ja) 2016-03-31 2022-07-11 サッカライド－ポリペプチドコンジュゲートの組成物およびその使用の方法
JP2023152185A Pending JP2023166591A (ja) 2016-03-31 2023-09-20 サッカライド－ポリペプチドコンジュゲートの組成物およびその使用の方法
JP2025095460A Pending JP2025124888A (ja) 2016-03-31 2025-06-09 サッカライド－ポリペプチドコンジュゲートの組成物およびその使用の方法

Country Status (4)

Country Link
US (2) US11058757B2 (enExample)
EP (2) EP3436061A4 (enExample)
JP (4) JP7164200B2 (enExample)
WO (1) WO2017173415A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3436061A4 (en) * 2016-03-31 2019-12-04 Liffey Biotech Limited Saccharide-polypeptide-conjugate compositions and methods of use thereof
MX2019007910A (es) 2016-12-30 2019-12-05 Sutrovax Inc Conjugados de polipeptido-antigeno con aminoacidos no naturales.
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
GB201711635D0 (en) * 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
GB201711637D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
US11491216B2 (en) 2017-09-07 2022-11-08 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US11389540B2 (en) 2017-09-07 2022-07-19 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
CA3074703A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
CA3074708A1 (en) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US11524076B2 (en) 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US12257295B2 (en) * 2017-10-04 2025-03-25 Pogona, LLC Saccharide-polypeptide conjugate compositions and methods of use thereof
KR102686858B1 (ko) * 2017-12-06 2024-07-19 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법
JP6950099B2 (ja) 2018-02-05 2021-10-13 サノフィ パスツール インコーポレイティッド 多価肺炎球菌多糖体−タンパク質複合体組成物
BR112020021296A2 (pt) 2018-04-18 2021-01-26 Sk Bioscience Co., Ltd. polissacarídeo capsular de streptococcus pneumoniae e conjugado imunogênico do mesmo
DK3817775T3 (da) * 2018-07-04 2024-09-16 Vaxcyte Inc Forbedringer i immunogene konjugater
MY206212A (en) * 2018-09-23 2024-12-04 Biological E Ltd Purified capsular polysaccharides of streptococcus pneumoniae
EA202191638A1 (ru) * 2018-10-12 2021-12-27 Байолоджикал И Лимитед Мультивалентная вакцина на основе конъюгата пневмококковый полисахарид-белок
US20220016229A1 (en) * 2018-12-12 2022-01-20 Pfizer Inc. Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
WO2020131763A2 (en) * 2018-12-19 2020-06-25 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CA3136278A1 (en) * 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
BR112021024491A8 (pt) * 2019-06-05 2023-04-11 Merck Sharp & Dohme Composição imunogênica, e, método para prevenir, tratar ou melhorar uma infecção, doença ou condição
WO2022035816A1 (en) * 2020-08-10 2022-02-17 Inventprise, Llc Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
US20240000912A1 (en) * 2020-11-04 2024-01-04 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CN115671274B (zh) * 2022-09-29 2024-03-12 普大生物科技(泰州)有限公司 一种载体蛋白与多糖共价键连接成结合物的方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150374811A1 (en) 2013-02-07 2015-12-31 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221906A (en) 1979-03-19 1980-09-09 American Cyanamid Company Stabilization of pneumococcal polysaccharides
US4242501A (en) 1979-08-08 1980-12-30 American Cyanamid Company Purification of pneumococcal capsular polysaccharides
US4686102A (en) 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
JP4057576B2 (ja) 2004-10-08 2008-03-05 財団法人浜松科学技術研究振興会 靴底用中敷
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
MX2009001412A (es) * 2006-08-07 2009-04-24 Harvard College Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
ITMI20130142A1 (it) * 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
CN104069488A (zh) * 2013-03-29 2014-10-01 北京科兴中维生物技术有限公司 多价肺炎球菌荚膜多糖-蛋白质共轭组合物及其制备方法
ES2865473T3 (es) 2013-07-10 2021-10-15 Sutro Biopharma Inc Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
JP6739333B2 (ja) 2013-07-11 2020-08-12 ノバルティス アーゲー 部位特異的化学酵素的タンパク質修飾
KR20240145064A (ko) 2015-03-26 2024-10-04 지피앤 백신즈 피티와이 엘티디 연쇄상구균 백신
LT3313436T (lt) 2015-06-23 2021-06-10 Biological E Limited Daugiavalentė pneumokokinė konjuguota vakcina
IL303998A (en) 2015-07-21 2023-08-01 Pfizer Immunogenic preparations containing conjugated capsular sugar antigens, kits containing them and their uses
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
EP3436061A4 (en) * 2016-03-31 2019-12-04 Liffey Biotech Limited Saccharide-polypeptide-conjugate compositions and methods of use thereof
CU24660B1 (es) 2016-09-30 2023-05-11 Biological E Ltd Composiciones de vacunas multivalentes que comprenden conjugados de polisacárido-proteína de streptococcus pneumoniae utilizando proteínas portadoras psaa y crm197
US12257295B2 (en) * 2017-10-04 2025-03-25 Pogona, LLC Saccharide-polypeptide conjugate compositions and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150374811A1 (en) 2013-02-07 2015-12-31 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Eur.J.Clin.Microbiol.Infect.Dis.，2014年，Vol.33，pp.465-470
Vaccine，2016年02月，Vol.34，pp.1648-1656

Also Published As

Publication number Publication date
EP3436061A2 (en) 2019-02-06
JP2023166591A (ja) 2023-11-21
US20220143167A1 (en) 2022-05-12
JP2025124888A (ja) 2025-08-26
JP2022130741A (ja) 2022-09-06
US20200113993A1 (en) 2020-04-16
EP4488286A2 (en) 2025-01-08
WO2017173415A2 (en) 2017-10-05
WO2017173415A3 (en) 2017-11-09
US11058757B2 (en) 2021-07-13
EP3436061A4 (en) 2019-12-04
EP4488286A3 (en) 2025-04-02
JP2019513821A (ja) 2019-05-30

Similar Documents

Publication Publication Date Title
JP7164200B2 (ja) サッカライド－ポリペプチドコンジュゲートの組成物およびその使用の方法
US20250262290A1 (en) Saccharide-polypeptide conjugate compositions and methods of use thereof
US11872274B2 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TWI789357B (zh) 多價肺炎球菌多醣-蛋白質共軛物組成物(二)
EP2056871B1 (en) Protein matrix vaccines and methods of making and administering such vaccines
EP3096785B1 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP2018518512A (ja) 多価肺炎球菌コンジュゲートワクチン
US20120231086A1 (en) Protein matrix vaccines of improved immunogenicity
WO2022035816A1 (en) Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
US12453764B2 (en) Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
US20240374699A1 (en) Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof
HK1249403A1 (en) Protein matrix vaccines and methods of making and administering such vac-cines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220711

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220823

TRDD Decision of grant or rejection written
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220823

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220914

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221013

R150 Certificate of patent or registration of utility model

Ref document number: 7164200

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250